Market Overview

Aastrom Announces Collaboration With CPC Clinical Research for the Phase 3 REVIVE Study in Critical Limb Ischemia


Aastrom Biosciences (Nasdaq: ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced a collaborative agreement with CPC Clinical Research, a non-profit, academic research organization led by William Hiatt, M.D. CPC will provide services related to the execution of Aastrom's Phase 3 REVIVE clinical studies for ixmyelocel-T, the company's expanded multicellular therapy.

"CPC has extensive experience in clinical trials research related to peripheral artery disease and wound healing," said Dr. Hiatt, president of CPC Clinical Research. "We are thrilled to collaborate with Aastrom on what we believe is one of the most well-designed clinical development programs we've seen for CLI patients. We share their commitment to advancing the REVIVE Phase 3 clinical program for ixmyelocel-T to regulatory approval and to help provide a promising therapy to CLI patients – a population with a significant unmet medical need. Aastrom's clinical development program is a critically important translational step in the development of cellular therapies to treat human disease, a key objective of the University of Colorado Stem Cell Center."


Related Articles (ASTM)

View Comments and Join the Discussion!

Posted-In: News FDA

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at